Cohen S, Nathan J A, Goldberg A L. Muscle wasting in disease: molecular mechanisms and promising therapies[J]. Nat Rev Drug Discov, 2015, 14(1): 58-74. [2]Porter C, Herndon D N, Sidossis L S, et al. The impact of severe burns on skeletal muscle mitochondrial function[J]. Burns, 2013, 39(6): 1039-1047. [3]Williams F N, Branski L K, Jeschke M G, et al. What, how, and how much should patients with burns be fed?[J]. Surg Clin North Am, 2011, 91(3): 609-629. [4]Egerman M A, Glass D J. Signaling pathways controlling skeletal muscle mass[J]. Crit Rev Biochem Mol Biol, 2014, 49(1): 59-68. [5]柴家科. 严重烧伤后骨骼肌消耗的机制与治疗前景思考[J]. 中华烧伤杂志, 2009, 25(4): 243-245. [6]Tzika A A, Astrakas L G, Cao H, et al. Murine intramyocellular lipids quantified by NMR act as metabolic biomarkers in burn trauma[J]. Int J Mol Med, 2008, 21(6): 825-832. [7]Wade C E, Mora A G, Shields B A, et al. Signals from fat after injury: plasma adipokines and ghrelin concentrations in the severely burned[J]. Cytokine, 2013, 61(1): 78-83. [8]O’Neill H M, Lally J S, Galic S, et al. AMPK phosphorylation of ACC2 is required for skeletal muscle fatty acid oxidation and insulin sensitivity in mice[J]. Diabetologia, 2014, 57(8): 1693-1702. [9]Niu Y, Yuan H, Fu L. Aerobic exercise’s reversal of insulin resistance by activating AMPKalpha-ACC-CPT1 signaling in the skeletal muscle of C57BL/6 mice[J]. Int J Sport Nutr Exerc Metab, 2010, 20(5): 370-380. [10]Bastin J. Regulation of mitochondrial fatty acid beta-oxidation in human: what can we learn from inborn fatty acid beta-？oxidation？ deficiencies?[J]. Biochimie, 2014, 96: 113-120. [11]Zhou G, Sebhat I K, Zhang B B. AMPK activators--potential therapeutics for metabolic and other diseases[J]. Acta Physiol (Oxf), 2009, 196(1): 175-190. [12]Grahame-Hardie D. AMP-activated protein kinase: a key regulator of energy balance with many roles in human disease[J]. J Intern Med, 2014, 276(6): 543-559. [13]王金霞, 任建功, 罗辉, 等. AMPK？2基因多态性与2型糖尿病及血清脂联素、颈动脉粥样硬化的关系[J]. 第三军医大学学报, 2012, 34(6): 530-533. [14]Zhang B B, Zhou G, Li C. AMPK: an emerging drug target for diabetes and the metabolic syndrome[J]. Cell Metab, 2009, 9(5): 407-416. [15]Zungu M, Schisler J C, Essop M F, et al. Regulation of AMPK by the ubiquitin proteasome system[J]. Am J Pathol, 2011, 178(1): 4-11. [16]Merritt E K, Thalacker-Mercer A, Cross J M, et al. Increased expression of atrogenes and TWEAK family members after severe burn injury in nonburned human skeletal muscle[J]. J Burn Care Res, 2013, 34(5): e297-e304.
